BACKGROUND: Clinical reports suggest that rather than directly driving cocaine use, stress may create a biological context within which other triggers for drug use become more potent. We hypothesize that stress-induced increases in corticosterone "set the stage" for relapse by promoting endocannabinoid-induced attenuation of inhibitory transmission in the prelimbic cortex (PL). METHODS: We have established a rat model for these stage-setting effects of stress. In this model, neither a stressor (electric footshock) nor stress-level corticosterone treatment alone reinstates cocaine seeking following self-administration and extinction, but each treatment potentiates reinstatement in response to an otherwise subthreshold cocaine priming dose (2.5 mg/kg, intraperitoneal). The contributions of endocannabinoid signaling in the PL to the effects of stress-level corticosterone on PL neurotransmission and cocaine seeking were determined using intra-PL microinfusions. Endocannabinoid-dependent effects of corticosterone on inhibitory synaptic transmission in the rat PL were determined using whole-cell recordings in layer V pyramidal neurons. RESULTS: Corticosterone application attenuated inhibitory synaptic transmission in the PL via cannabinoid receptor type 1 (CB1R)- and 2-arachidonoylglycerol-dependent inhibition of gamma-aminobutyric acid release without altering postsynaptic responses. The ability of systemic stress-level corticosterone treatment to potentiate cocaine-primed reinstatement was recapitulated by intra-PL injection of corticosterone, the CB1R agonist WIN 55,212-2, or the monoacylglycerol lipase inhibitor URB602. Corticosterone effects on reinstatement were attenuated by intra-PL injections of either the CB1R antagonist, AM251, or the diacylglycerol lipase inhibitor, DO34. CONCLUSIONS: These findings suggest that stress-induced increases in corticosterone promote cocaine seeking by mobilizing 2-arachidonoylglycerol in the PL, resulting in CB1R-mediated attenuation of inhibitory transmission in this brain region.
BACKGROUND: Clinical reports suggest that rather than directly driving cocaine use, stress may create a biological context within which other triggers for drug use become more potent. We hypothesize that stress-induced increases in corticosterone "set the stage" for relapse by promoting endocannabinoid-induced attenuation of inhibitory transmission in the prelimbic cortex (PL). METHODS: We have established a rat model for these stage-setting effects of stress. In this model, neither a stressor (electric footshock) nor stress-level corticosterone treatment alone reinstates cocaine seeking following self-administration and extinction, but each treatment potentiates reinstatement in response to an otherwise subthreshold cocaine priming dose (2.5 mg/kg, intraperitoneal). The contributions of endocannabinoid signaling in the PL to the effects of stress-level corticosterone on PL neurotransmission and cocaine seeking were determined using intra-PL microinfusions. Endocannabinoid-dependent effects of corticosterone on inhibitory synaptic transmission in the ratPL were determined using whole-cell recordings in layer V pyramidal neurons. RESULTS:Corticosterone application attenuated inhibitory synaptic transmission in the PL via cannabinoid receptor type 1 (CB1R)- and 2-arachidonoylglycerol-dependent inhibition of gamma-aminobutyric acid release without altering postsynaptic responses. The ability of systemic stress-level corticosterone treatment to potentiate cocaine-primed reinstatement was recapitulated by intra-PL injection of corticosterone, the CB1R agonist WIN 55,212-2, or the monoacylglycerol lipase inhibitor URB602. Corticosterone effects on reinstatement were attenuated by intra-PL injections of either the CB1R antagonist, AM251, or the diacylglycerol lipase inhibitor, DO34. CONCLUSIONS: These findings suggest that stress-induced increases in corticosterone promote cocaine seeking by mobilizing 2-arachidonoylglycerol in the PL, resulting in CB1R-mediated attenuation of inhibitory transmission in this brain region.
Authors: Daisuke Ogasawara; Hui Deng; Andreu Viader; Marc P Baggelaar; Arjen Breman; Hans den Dulk; Adrianus M C H van den Nieuwendijk; Adriann M C H van den Nieuwendijk; Marjolein Soethoudt; Tom van der Wel; Juan Zhou; Herman S Overkleeft; Manuel Sanchez-Alavez; Simone Mori; Simone Mo; William Nguyen; Bruno Conti; Xiaojie Liu; Yao Chen; Qing-Song Liu; Benjamin F Cravatt; Mario van der Stelt Journal: Proc Natl Acad Sci U S A Date: 2015-12-14 Impact factor: 11.205
Authors: Michael T Stefanik; Khaled Moussawi; Yonatan M Kupchik; Kyle C Smith; Rachel L Miller; Mary L Huff; Karl Deisseroth; Peter W Kalivas; Ryan T LaLumiere Journal: Addict Biol Date: 2012-07-24 Impact factor: 4.280
Authors: Charlotte C Bavley; Robert N Fetcho; Caitlin E Burgdorf; Alexander P Walsh; Delaney K Fischer; Baila S Hall; Nicole M Sayles; Natalina H Contoreggi; Jonathan E Hackett; Susan A Antigua; Rachel Babij; Natalia V De Marco García; Thomas L Kash; Teresa A Milner; Conor Liston; Anjali M Rajadhyaksha Journal: Mol Psychiatry Date: 2019-09-09 Impact factor: 15.992
Authors: Elizabeth M Doncheck; Gage T Liddiard; Chaz D Konrath; Xiaojie Liu; Laikang Yu; Luke A Urbanik; Matthew R Herbst; Margot C DeBaker; Nicholas Raddatz; Erik C Van Newenhizen; Jacob Mathy; Marieke R Gilmartin; Qing-Song Liu; Cecilia J Hillard; John R Mantsch Journal: Neuropsychopharmacology Date: 2020-04-17 Impact factor: 7.853
Authors: Elizabeth M Doncheck; Eden M Anderson; Chaz D Konrath; Gage T Liddiard; Margot C DeBaker; Luke A Urbanik; Matthew C Hearing; John R Mantsch Journal: J Neurosci Date: 2021-04-20 Impact factor: 6.167
Authors: Hyo Sun Roh; Bo Ra Park; Eun Young Jang; Jin Sook Kim; Young S Gwak Journal: Evid Based Complement Alternat Med Date: 2018-10-17 Impact factor: 2.629
Authors: Carol A Gianessi; Stephanie M Groman; Summer L Thompson; Ming Jiang; Mario van der Stelt; Jane R Taylor Journal: Addict Biol Date: 2019-05-06 Impact factor: 4.280